Skip to main content
AstraZenecaPartnership

AstraZeneca Partners with insitro in $40M AI Drug Discovery Deal

Source: Autobound Signal API · 80 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca has partnered with AI biotech insitro in a drug discovery collaboration valued at up to $1.5 billion, including $40 million up front.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). It also...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

Takes effect
Oct 15, 2026
Location
London, England, United Kingdom

Companies

  • insitroPartnerinsitro.com

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Oct 15, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/270a669a-1a25-22f4-40e0-b8069577e90b returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "270a669a-1a25-22f4-40e0-b8069577e90b",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-10-15T10:22:30+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.globalbankingandfinance.com/astrazeneca-strikes-40-million-ai-drug-discovery-deal/",
    "title": "AstraZeneca Partners with insitro in $40M AI Drug Discovery Deal - Global Banking & Finance Review",
    "excerpt": "By Patrick Wingrove LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. Insitro will use its \"Virtual Human\" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). It also teamed...",
    "summary": "AstraZeneca has partnered with AI biotech insitro in a drug discovery collaboration valued at up to $1.5 billion, including $40 million up front.",
    "location": "London, United Kingdom",
    "planning": false,
    "image_url": "https://www.globalbankingandfinance.com/i/cloud-86385a72-63c3-4630-80f7-c240bbcf26ea/width=1200,height=630,quality=80,format=auto,fit=cover/",
    "confidence": 0.95,
    "published_at": "2026-10-15T10:22:30Z",
    "location_data": [
      {
        "city": "London",
        "state": "England",
        "region": "Northern Europe",
        "country": "United Kingdom",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-15",
    "article_sentence": "AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday.",
    "related_company_name": "insitro",
    "related_company_domain": "insitro.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.